These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 162327)

  • 1. [Clinical experiences with the radiation-sensitizing agent misonidazole].
    Kogelnik HD; Szepesi T; Kärcher KH; Seitz W
    Strahlentherapie Sonderb; 1978; 75():115-9. PubMed ID: 162327
    [No Abstract]   [Full Text] [Related]  

  • 2. New side effect of the hypoxic cell sensitizer, misonidazole.
    Partington J; Koziol D; Chapman D; Rabin H; Urtasun RC
    Cancer Treat Rep; 1979 Jan; 63(1):123-5. PubMed ID: 217536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with misonidazole: high dose fractions versus daily low doses.
    Kogelnik HD
    Cancer Clin Trials; 1980; 3(2):179-86. PubMed ID: 6253098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical experience with daily doses of misonidazole (author's transl)].
    Kogelnik HD; Reinartz G; Szepesi T; Seitz W; Wurst F; Mamoli B; Wessely P; Stark H
    Strahlentherapie; 1980 Nov; 156(11):758-64. PubMed ID: 7434385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical experiences with the radiosensitizer Misonidazol (author's transl)].
    Bamberg M; Tamulevicius P; Streffer C; Scherer E
    Strahlentherapie; 1981 Aug; 157(8):524-36. PubMed ID: 7268822
    [No Abstract]   [Full Text] [Related]  

  • 6. Misonidazole-a drug for trial in radiotherapy and oncology.
    Dische S; Saunders MI; Flockhart IR; Lee ME; Anderson P
    Int J Radiat Oncol Biol Phys; 1979 Jun; 5(6):851-60. PubMed ID: 227822
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical evaluation of hypoxic cell sensitizer (Misonidazole)].
    Asakawa H; Watarai J; Hoshino T
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1225-30. PubMed ID: 6732250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. I.V. misonidazole (NSC 261037). Report of initial clinical experience.
    Schwade JG; Strong JM; Gangji D
    Cancer Clin Trials; 1981; 4(1):33-9. PubMed ID: 7214660
    [No Abstract]   [Full Text] [Related]  

  • 9. The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.
    White RA; Workman P; Brown JM
    Radiat Res; 1980 Dec; 84(3):542-61. PubMed ID: 6450431
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical trials of hypoxic cell sensitizer misonidazole].
    Onoyama Y
    Gan No Rinsho; 1983 May; 29(6):718-25. PubMed ID: 6348345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical studies of combined therapy of radiation and local injection of misonidazole].
    Hong SS; Abe Y; Isobe Y; Yamakawa M; Kaneta K; Kawaguchi T; Matsuzawa T; Umegaki Y
    Nihon Igaku Hoshasen Gakkai Zasshi; 1983 May; 43(5):675-84. PubMed ID: 6622246
    [No Abstract]   [Full Text] [Related]  

  • 12. Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer.
    Wasserman TH; Phillips TL; Johnson RJ; Gomer CJ; Lawrence GA; Sadee W; Marques RA; Levin VA; VanRaalte G
    Int J Radiat Oncol Biol Phys; 1979 Jun; 5(6):775-86. PubMed ID: 227821
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical experience with misonidazole.
    Dische S; Saunders MI
    Br J Cancer Suppl; 1978 Jun; 3():311-3. PubMed ID: 277252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Local administration of radiosensitizer misonidazole].
    Otsuka S; Suda K; Yamashita J; Gi H; Oda Y; Takeuchi J; Handa H; Ono K
    No To Shinkei; 1983 Mar; 35(3):249-55. PubMed ID: 6687999
    [No Abstract]   [Full Text] [Related]  

  • 15. [Radiosensitizing effect of misonidazole in radiotherapy for intracranial tumors].
    Otsuka S
    Nihon Geka Hokan; 1982 Nov; 51(6):892-906. PubMed ID: 7171270
    [No Abstract]   [Full Text] [Related]  

  • 16. Skin rashes associated with the administration of the 2-nitroimidazole, misonidazole.
    Saunders MI; Dische S; Kogelnik HD; Sealy R; Lenox-Smith I
    Cancer Treat Rep; 1980; 64(2-3):263-8. PubMed ID: 6447539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation Therapy Oncology Group clinical trials with misonidazole.
    Wasserman TH; Stetz J; Phillips TL
    Cancer; 1981 May; 47(10):2382-90. PubMed ID: 7023642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical testing of the radiosensitizer RO-07-0582 (misonidazole). Dose tolerance, toxicity and pharmacokinetic studies, preliminary report (author's transl)].
    Bataini JP; Bernier J; de Narbonne J; Brugère J; Jaulerry C; Brunin F
    Bull Cancer; 1978; 65(4):482-5. PubMed ID: 371710
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical trials of misonidazole in the United States.
    Wasserman TH; Stetz J; Phillips TL
    Cancer Clin Trials; 1981; 4(1):7-16. PubMed ID: 7214664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Misonidazole peripheral neuropathy: its relationship to plasma concentration and other drugs.
    Walker MD; Strike TA
    Cancer Clin Trials; 1980; 3(2):105-9. PubMed ID: 6253094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.